Rallybio Corp (RLYB) - Net Assets
Based on the latest financial reports, Rallybio Corp (RLYB) has net assets worth $57.96 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($62.26 Million) and total liabilities ($4.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Rallybio Corp (RLYB) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $57.96 Million |
| % of Total Assets | 93.09% |
| Annual Growth Rate | 22.84% |
| 5-Year Change | -67.0% |
| 10-Year Change | N/A |
| Growth Volatility | 268.84 |
Rallybio Corp - Net Assets Trend (2019–2025)
This chart illustrates how Rallybio Corp's net assets have evolved over time, based on quarterly financial data. Also explore Rallybio Corp (RLYB) total assets for the complete picture of this company's asset base.
Annual Net Assets for Rallybio Corp (2019–2025)
The table below shows the annual net assets of Rallybio Corp from 2019 to 2025. For live valuation and market cap data, see RLYB market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $57.96 Million | -6.00% |
| 2024-12-31 | $61.65 Million | -41.94% |
| 2023-12-31 | $106.18 Million | -37.29% |
| 2022-12-31 | $169.32 Million | -3.58% |
| 2021-12-31 | $175.60 Million | +29.12% |
| 2020-12-31 | $136.00 Million | +706.66% |
| 2019-12-31 | $16.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rallybio Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28143100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.01% |
| Other Comprehensive Income | $18.00K | 0.03% |
| Other Components | $359.93 Million | 621.04% |
| Total Equity | $57.96 Million | 100.00% |
Rallybio Corp Competitors by Market Cap
The table below lists competitors of Rallybio Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sheetal Cool Products Limited
NSE:SCPL
|
$43.49 Million |
|
Nandan Denim Limited
NSE:NDL
|
$43.49 Million |
|
Euro Yatirim Holding AS
IS:EUHOL
|
$43.51 Million |
|
Mad Paws Holdings Ltd
AU:MPA
|
$43.51 Million |
|
Haoxi Health Technology Limited Class A Ordinary Shares
NASDAQ:HAO
|
$43.48 Million |
|
LTKM Bhd
KLSE:7085
|
$43.48 Million |
|
Kocom Co. Ltd
KQ:015710
|
$43.47 Million |
|
Minehub Technologies Inc
V:MHUB
|
$43.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rallybio Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 61,654,000 to 57,956,000, a change of -3,698,000 (-6.0%).
- Net loss of 8,978,000 reduced equity.
- Share repurchases of 16,000 reduced equity.
- Other comprehensive income decreased equity by 50,000.
- Other factors increased equity by 5,346,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.98 Million | -15.49% |
| Share Repurchases | $16.00K | -0.03% |
| Other Comprehensive Income | $-50.00K | -0.09% |
| Other Changes | $5.35 Million | +9.22% |
| Total Change | $- | -6.00% |
Book Value vs Market Value Analysis
This analysis compares Rallybio Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.91x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.55x to 0.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $6.06 | $9.41 | x |
| 2020-12-31 | $48.91 | $9.41 | x |
| 2021-12-31 | $43.72 | $9.41 | x |
| 2022-12-31 | $42.57 | $9.41 | x |
| 2023-12-31 | $21.00 | $9.41 | x |
| 2024-12-31 | $11.33 | $9.41 | x |
| 2025-12-31 | $10.30 | $9.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rallybio Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1046.39%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.07x
- Recent ROE (-15.49%) is above the historical average (-52.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -104.54% | 0.00% | 0.00x | 1.28x | $-19.31 Million |
| 2020 | -19.45% | 0.00% | 0.00x | 1.04x | $-40.05 Million |
| 2021 | -26.77% | 0.00% | 0.00x | 1.04x | $-64.57 Million |
| 2022 | -39.37% | 0.00% | 0.00x | 1.07x | $-83.59 Million |
| 2023 | -70.22% | 0.00% | 0.00x | 1.09x | $-85.18 Million |
| 2024 | -93.71% | -9084.12% | 0.01x | 1.10x | $-63.94 Million |
| 2025 | -15.49% | -1046.39% | 0.01x | 1.07x | $-14.77 Million |
Industry Comparison
This section compares Rallybio Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rallybio Corp (RLYB) | $57.96 Million | -104.54% | 0.07x | $43.48 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more